Ponatinib Hydrochloride bulk supplier for pharma manufacturers

Ponatinib Hydrochloride 10 mg, 15 mg, 30 mg, 45 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg, 15 mg, 30 mg, 45 mg

Reference Brands: Iclusig (USA)

Ponatinib is a third-generation tyrosine kinase inhibitor that targets BCR‑ABL, including the T315I mutation, which is resistant to earlier TKIs. It is used primarily to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Ponatinib Hydrochloride — third party manufacturing & bulk supply

Ponatinib Hydrochloride 10 mg, 15 mg, 30 mg, 45 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ponatinib Hydrochloride is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ponatinib Hydrochloride listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ponatinib Hydrochloride →

Back to Listing

Frequently Asked Questions

Ponatinib Hydrochloride is used for the treatment of certain types of blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients resistant to other therapies.

It is made from ponatinib hydrochloride, a tyrosine kinase inhibitor synthesized to block the activity of the BCR-ABL protein that drives cancer cell growth.

The commonly known trade name is Iclusig.

Iclusig is marketed by Takeda Pharmaceuticals.

The generic name is ponatinib hydrochloride.

The well-known brand name is Iclusig.

Ponatinib Hydrochloride is manufactured in countries including India, the USA, and select EU regions by branded and generic pharmaceutical manufacturers.